Geraldine Harriman, Author at HotSpot Therapeutics

July 31, 2025

A “Complex” Solution to a “Complex” Problem? Attacking KRASG12X Colorectal Cancer Through the CBM Signalosome

As scientists, we are accustomed to learning something new about targets (and the modulation thereof) that moves the field forward...

by Geraldine Harriman

Read more

February 7, 2024

Drug Discovery: Taking Inspiration from Facial Recognition

At HotSpot, we’re harnessing insights from nature by pinpointing specialized protein on/off switches, or pockets, called “natural hotspots.” To date,...

by Geraldine Harriman

Read more

December 6, 2022

What Took So Long? – How Tech Has Finally Caught Up with Transcription Factors

HotSpot Therapeutics recently announced a strategic collaboration with AbbVie to develop IRF5 transcription factor inhibitors for autoimmune diseases. The following…

by Geraldine Harriman

Read more

August 23, 2019

Hotspots meet DNA-encoded libraries

DNA encoded libraries (DEL) have received a lot of attention over the past few years. They’ve been hailed as “highly...

by Geraldine Harriman

Read more

June 30, 2019

Biocentury Innovations shines a new light on allostery

I was excited to participate in Allison Johnson’s recent Biocentury article reflecting on the growing interest of industry in allostery and why...

by Geraldine Harriman

Read more

March 11, 2019

HotSpot Frequently Asked Questions

What is a regulatory hotspot? A regulatory hotspot is a privileged allosteric site used by nature to regulate the function...

by Geraldine Harriman

Read more